1266084-51-8

Basic information

• Product Name: acoziborole
• Synonyms: acoziborole
• CAS NO: 1266084-51-8
• Molecular Weight: 367.108
• Mol File: 1266084-51-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: acoziborole(CAS DataBase Reference)
• NIST Chemistry Reference: acoziborole(1266084-51-8)
• EPA Substance Registry System: acoziborole(1266084-51-8)

Safety Data

• Hazardous Substances Data: 1266084-51-8(Hazardous Substances Data)

Usage

General Description

Acoziborole is a chemical compound which acts as a potent and selective inhibitor of trypanosomal protein translation. This makes it a promising candidate for the treatment of trypanosomiasis, a parasitic disease caused by the Trypanosoma brucei parasite. Acoziborole works by targeting and inhibiting the enzyme trypanosomal alternative oxidase, leading to the disruption of the parasite's energy metabolism and ultimately causing its death. Studies have shown that acoziborole has low toxicity in humans and has demonstrated significant efficacy in preclinical trials, making it a potentially valuable tool in the fight against trypanosomiasis, a disease that primarily affects people in sub-Saharan Africa.

Upstream product

• 1266084-49-4 6-amino-3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol hydrochloride 
• 189807-21-4 2-trifluoromethyl-4-fluorobenzoyl chloride 
• 1266084-47-2 3,3-dimethyl-6-nitrobenzo[c][1,2]oxaborol-1(3H)-ol 
• 1008106-85-1 2-(2'-bromophenyl)-6-butyl[1,3,6,2]dioxazaborocan 
• 221352-10-9 3,3-dimethylbenzo [c][1,2]oxaborol-1(3H)-ol 
• 7073-69-0 2-(2-bromophenyl)propanol 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 1266320-01-7 6-amino-3,3-dimethylbenzo[c][1,2]oxaborol-1(3H)-ol 
• 244205-40-1 (2-bromophenyl)boronic acid 

Relevant articles and documents

BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS

This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The compounds are of the following formula: wherein R1 is a member selected from alkyl or aryl or heteroaryl, in which at least one substituent on said alkyl or said aryl or said heteroaryl is optionally substituted with a member selected from halogen, C1 or C2 or C3 or C4 or C5 or C6 unsubstituted alkyl, C1 or C2 or C3or C4 or C5 or C6 unsubstituted alkoxy, halosubstituted C1 or C2 or C3or C4 or C5 or C6 alkyl, halosubstituted C1 or C2 or C3 or C4 or C5 or C6 alkoxy, unsubstituted C1 or C2 or C3 or C4or C5 or C6 alkylthio, unsubstituted phenyl; and X is aryl or heteroaryl, in which one substituent on said aryl or said heteroaryl is a member selected from halogen, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkoxy, halosubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl, halosubstituted C1 or C2 or C3 or C4 or C5 or C6 alkoxy, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkylthio, unsubstituted phenyl or a salt thereof.